DORIDEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Doriden, and when can generic versions of Doriden launch?
Doriden is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in DORIDEN is glutethimide. There are four drug master file entries for this compound. Additional details are available on the glutethimide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DORIDEN?
- What are the global sales for DORIDEN?
- What is Average Wholesale Price for DORIDEN?
Summary for DORIDEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 25 |
| Patent Applications: | 3,023 |
| DailyMed Link: | DORIDEN at DailyMed |
US Patents and Regulatory Information for DORIDEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | DORIDEN | glutethimide | CAPSULE;ORAL | 009519-008 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | DORIDEN | glutethimide | TABLET;ORAL | 009519-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | DORIDEN | glutethimide | TABLET;ORAL | 009519-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
